{"nctId":"NCT03185065","briefTitle":"Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis","startDateStruct":{"date":"2017-10-04","type":"ACTUAL"},"conditions":["Fatigue in Multiple Sclerosis"],"count":141,"armGroups":[{"label":"Arm A","type":"EXPERIMENTAL","interventionNames":["Drug: Amantadine","Drug: Modafinil","Drug: Methylphenidate","Drug: Placebos"]},{"label":"Arm B","type":"EXPERIMENTAL","interventionNames":["Drug: Amantadine","Drug: Modafinil","Drug: Methylphenidate","Drug: Placebos"]},{"label":"Arm C","type":"EXPERIMENTAL","interventionNames":["Drug: Amantadine","Drug: Modafinil","Drug: Methylphenidate","Drug: Placebos"]},{"label":"Arm D","type":"EXPERIMENTAL","interventionNames":["Drug: Amantadine","Drug: Modafinil","Drug: Methylphenidate","Drug: Placebos"]}],"interventions":[{"name":"Amantadine","otherNames":[]},{"name":"Modafinil","otherNames":[]},{"name":"Methylphenidate","otherNames":[]},{"name":"Placebos","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Age 18 years and older.\n* Females of childbearing age must have a negative urine pregnancy test at baseline and use an effective method of contraception during the study.\n* Diagnosis of MS (according to the 2010 McDonald criteria).\n* Expanded Disability Status Scale (EDSS) score at the time of screening 0.0-7.0.\n* Fatigue reportedly present and screening Modified Fatigue Impact Scale (MFIS) score more than 33.\n* At least a two-week washout for any fatigue-related drug, including study medications.\n\nExclusion criteria:\n\n* Neurodegenerative disorders other than relapsing or progressive MS.\n* Breastfeeding or pregnant.\n* History of coronary artery disease or congestive heart failure.\n* Uncontrolled hypertension at screening (history of high blood pressure and screening systolic blood pressure \\>160 or diastolic blood pressure\\>100).\n* Glomerular Filtration Rate (GFR) (glomerular filtration rate) \\< 50.\n* Abnormal liver function at screening (AST or Alanine Aminotransferase (ALT) more than twice the upper limit of normal).\n* Terminal medical conditions.\n* Currently treated for active malignancy.\n* Planned surgery or move within 8 months of screening.\n* Alcohol or substance abuse in the past year (except marijuana or other cannabinoids).\n* A history of intolerance or allergic or anaphylactic reaction to amantadine, modafinil, methylphenidate or any component of the preparation.\n* Clinically unstable medical or psychiatric disorders that require acute treatment as determined by the PI.\n* Concurrent use of monoamine oxidase inhibitors-B.\n* Hypersensitivity/idiosyncrasy to sympathomimetic amines\n* Inability to communicate or answer the questionnaires in English or Spanish.\n* Severe untreated anemia (blood hemoglobin \\<9gr/dl)\n* History of untreated hypothyroidism\n* History of untreated sleep apnea\n* History of long QT syndrome, atrial fibrillation or tachyarrhythmias (other than sinus tachycardia)\n* History of ischemic or hemorrhagic stroke\n* History of glaucoma\n* History of Tourette syndrome","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Modified Fatigue Impact Scale (MFIS) Score","description":"MFIS score during the fifth week of treatment period. The total score of the MFIS ranges from 0 to 84. Higher scores denote more severe fatigue.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.6","spread":null},{"groupId":"OG001","value":"41.3","spread":null},{"groupId":"OG002","value":"39.0","spread":null},{"groupId":"OG003","value":"38.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Quality of Life in Neurological Disorders (Neuro-QoL) Item Bank - Fatigue Score","description":"Neuro-QoL Item Bank - Fatigue T score during the fifth week of treatment period. T-score distributions rescale raw scores into standardized scores with a mean of 50 and a standard deviation (SD) of 10. Higher T-scores denote more severe fatigue.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.1","spread":null},{"groupId":"OG001","value":"53.0","spread":null},{"groupId":"OG002","value":"52.5","spread":null},{"groupId":"OG003","value":"52.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Epworth Sleepiness Scale (ESS) Score","description":"ESS score during the fifth week of treatment period. The ESS score can range from 0 to 24. The higher the score, the higher that person's average sleep propensity in daily life, or their 'daytime sleepiness'.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","spread":null},{"groupId":"OG001","value":"9.3","spread":null},{"groupId":"OG002","value":"8.3","spread":null},{"groupId":"OG003","value":"8.8","spread":null}]}]}]},{"type":"POST_HOC","title":"Acceptability of Treatment as Assessed by a Single Question Questionnaire","description":"Participants will answer yes or no to this question: \"Taken into consideration the possible benefits and/or disadvantages of this medication, would you choose it, going forward to treat your MS fatigue?\". The number of participants who answered \"Yes\" to this question is reported here.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"55","spread":null},{"groupId":"OG003","value":"55","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":124},"commonTop":["Nervous system disorders","Psychiatric disorders","Gastrointestinal disorders","General disorders","Cardiac disorders"]}}}